Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals PLC

www.jazzpharma.com

Latest From Jazz Pharmaceuticals PLC

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

Commercial Financing

Deals Driving Oncology: ImmunoGen CEO Mark Enyedy on Biopharma’s Year Ahead

Cancer continues to reign in 2018 as the emperor of all maladies, with almost boundless opportunities for companies with a solid base in new science and a differentiated therapy set that can be tailored to the needs of individual patients not served by the current standard of care. ImmunoGen CEO Mark Enyedy tells In Vivo that there’s never been a better time for drugmakers in the oncology marketplace.

Deals Leadership

EU Filings For Amgen/UCB’s Evenity, iv Relenza From GSK, And A New PRIME Product

Products submitted for approval in the EU in recent weeks include Amgen/UCB’s potential new treatment for osteoporosis, romosozumab, an iv formulation of GSK’s flu treatment, zanamivir, and avacopan, a new immunosuppressant from ChemoCentryx that is getting support through the EMA’s PRIME scheme.

Europe Regulation

Copay Kickback Enforcement Gains Momentum: United Therapeutics Settles Charges

Settlement is first involving a copay assistance program operated through Caring Voice Coalition since the HHS Office of Inspector General rescinded a safe harbor for the charity's activities in late November. Is it the first of a wave?

Legal Issues Pricing Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Hepatic (Liver)
  • Neurology, Nervous System
  • Alias(es)
  • Jazz Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Jazz Pharmaceuticals PLC
  • Senior Management
  • Bruce C Cozadd, Chmn. & CEO
    Matthew Young, EVP, CFO
    Karen Smith, MD, PhD, Global Head, R&D & CMO
    Michael P Miller, SVP, US Commercial
  • Contact Info
  • Jazz Pharmaceuticals PLC
    Phone: 1 634 7800
    Connaught House, 4th Fl.
    One Burlington
    Dublin 4, CA
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register